You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.
While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.
With the EUA, LabCorp is able to sell the test kit directly to consumers without a prescription, making it the first over-the-counter COVID-19 test in the US.
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
The RT-PCR-based test was first authorized in March for the detection of SARS-CoV-2 nucleic acid in specimens collected by a healthcare provider.
The agreement will initially focus on making available assays developed and validated by LabCorp's Covance business, with the first assays targeting oncology.
The method uses heat for extraction, which the company said will improve test turnaround time and reduce reliance on nucleic acid extraction reagents.
Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.
Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.
Mission Bio will use a recent $70 million funding round to develop quality control assays using its Tapestri single-cell analysis platform.
Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner.
Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.
A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.
In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.